A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer-Reference-Cited by-同舟云学术

A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer

Published:2014-10-18 Issue:9 Volume:136 Page:2216-2227
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Liu Liang¹²³,Xu Huaxiang¹²³,Wang Wenquan¹²³,Wu Chuntao¹²³,Chen Yong⁴,Yang Jingxuan⁵,Cen Putao⁶⁷,Xu Jin¹²³,Liu Chen¹²³,Long Jiang¹²³,Guha Sushovan⁸⁶,Fu Deliang⁹,Ni Quanxing¹²³,Jatoi Aminah¹⁰,Chari Suresh¹¹¹²,McCleary-Wheeler Angela L.¹³,Fernandez-Zapico Martin E.¹³,Li Min¹²³⁵,Yu Xianjun¹²³

Affiliation:

1. Pancreatic Cancer Institute; Fudan University Shanghai Cancer Center; China

2. Department of Pancreatic and Hepatobiliary Surgery; Fudan University Shanghai Cancer Center; China

3. Department of Oncology; Shanghai Medical College, Fudan University; Shanghai China

4. Division of Biostatistics; School of Public Health, The University of Texas Health Science Center at Houston; TX

5. The Vivian L. Smith Department of Neurosurgery; The University of Texas Medical School at Houston; Houston TX

6. Department of Internal Medicine; The University of Texas Medical School at Houston; TX

7. Division of Oncology; The University of Texas Medical School at Houston; TX

8. Division of Gastroenterology; Hepatology and Nutrition, The University of Texas Medical School at Houston; TX

9. Department of Pancreatic Surgery; Huashan Hospital; Shanghai China

10. Department of Oncology; Mayo Clinic; Rochester MN

11. Division of Gastroenterology and Hepatology; Mayo Clinic; Rochester MN

12. Department of Internal Medicine; Mayo Clinic; Rochester MN

13. Schulze Center for Novel Therapeutics, Mayo Clinic; Rochester MN

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference34 articles.

1. Pancreatic cancer;Vincent;Lancet,2011

2. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) NCCN.org

3. The prognostic and predictive value of serum CA19.9 in pancreatic cancer;Humphris;Ann Oncol,2012

4. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma;Ferrone;J Clin Oncol,2006

5. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head;Evans;J Clin Oncol,2008

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guidelines for holistic integrative management of pancreatic cancer;Holistic Integrative Oncology;2024-07-08

2. Development of a radiomics-based model to predict occult liver metastases of pancreatic ductal adenocarcinoma: a multicenter study;International Journal of Surgery;2023-12-04

3. Case Report: Overcoming challenges in pancreatic cancer with liver metastases: a personalized therapeutic odyssey of TACE, ablation, and immunotherapy;Frontiers in Immunology;2023-10-11

4. Prediction of postoperative liver metastasis in pancreatic ductal adenocarcinoma based on multiparametric magnetic resonance radiomics combined with serological markers: a cohort study of machine learning;Abdominal Radiology;2023-10-11

5. High expression ITGA2 affects the expression of MET, PD-L1, CD4 and CD8 with the immune microenvironment in pancreatic cancer patients;Frontiers in Immunology;2023-10-10